Evaluation of Skin Quality Improvement

• Status: Completed
• Trial end date: 2018-07-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Steve Yoelin M.D. Medical Associates, Inc.
• Collaborator: Allergan
• Treatments: abobotulinumtoxinA; Anesthetics; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Ability to follow study instructions and likely to complete all required visits

• Written consent has been obtained

• Written authorization for "Use and Release of Health and Research Study Information" has been obtained

• Subjects who are Fitzpatrick Skin Types II-IV

Exclusion Criteria:

• Subjects must be Onabotulinum Toxin Type A naive; if subject has had Onabotulinum Toxin Type A administered in the face in the previous 12 months they are excluded

• Subjects must be dermal filler naïve in the lateral canthal region and midface regions

• Subjects must be energy or light device naïve

• Subjects must have average or below-average lifetime sun exposure

• Subjects must be free of inflammatory skin disease(s)